it's scientifically proved that COVID-19 is not death or survival. The disease is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems called #longCOVID.
1/
Q: What was the aim of this study?
Scientists wanted to evaluate the detailed assessment of kidney outcomes in long COVID.
2/
What did scientists do?From Mar 2020-Mar2021 they built a cohort of:
Total: 1,726,683 people
☆89,216 were 30-day COVID-19 survivors
☆1,637,467 non-infected controls
They examined risks of decline in kidney fuction&major adverse kidney events(decline in kidney function≥50%)
Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in
association with various COVID-19 vaccines and the emergence of variants in the Kingdom of Bahrain.
AlQahtani et al., 2021
1/
We know that:
1. Vaccines were designed against the original variants
2. The virus is keep mutating
3. Breakthrough infections occur.
4. Vaccines protects against severe illness& death
So, they are Critical questions that needs to be asked.
2/
Q: What was the aim of this study?
1.What is the effectiveness of various vaccines in
preventing infection, symptomatic disease, hospitalization,ICU admission&death
2.What are the clinical consequences of post-vaccination infections in the context of
emerging variants
3/
The study investigated 6 Month Safety and Efficacy of the Pfizer Vaccine:
How?
A total of ~47,000 including 44,165 ≥16-year-old participants& 2,264 12-15-year-old participants were randomized to receive 2 doses, 21 days apart, of 30 μg vaccine or placebo.
1/
What do they report here?
Study endpoints reported here are vaccine efficacy (VE) against laboratory-confirmed COVID-19 and safety data, both up to 6 months post-vaccination.
2/
What did they find?
☆Pfizer vaccine continued to be safe and well tolerated.
☆VE against COVID-19 was 91% through up to 6 months of follow-up
☆VE of 86%‒100% was seen across countries and in populations with diverse characteristics of age,
3/
This work aim at evaluating the immunogenicity of the Sinopharm, antibody responses against different SARS-CoV-2 variants of concern in individuals in Sri Lanka.
1/
What did they do?
They measured the SARS-CoV-2-specific antibodies (abs) in 282 individuals 2 weeks after 2d dose.
2/
Some technical details😉 on what they measured.
sero - at baseline,& ACE2 receptor blocking abs, abs to the RBD of the wild type (WT), B.1.1.7, B.1.351 and B.1.617.2, ex vivo&
cultured IFNγ ELISpot assays, intracellular cytokine secretion assays and B cell ELISpot assays.
3/
#COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors
☆Up to 20%–30% of patients hospitalized with COVID-19 have evidence of myocardial involvement.
1/
☆Acute cardiac injury in patients hospitalized with COVID19 is associated with higher morbidity&mortality.
☆Myocarditis from viralpathogens can evolve into overt or subclinical myocardial dysfunction, and cause death.This raises concerns 4 patients recovering from COVID-19.
2/
☆Some patients will have subclinical and possibly overt cardiovascular abnormalities.
☆Patients with ostensibly recovered cardiac function may still be at risk of cardiomyopathy and cardiac arrhythmias.
3/